VK2735 (weight loss pill) from Viking Therapeutics $VKTX (+3.27%) delivers. At a dose of 100mg, testers lost an average of 8.2% of their body weight over 28 days. VK2735 is not only very effective but also well tolerated.
The company's turnover at the end of the last financial year was "USD 0.00 million2 with a profit of USD -85.90 million. However, the current market capitalization is USD 7.50 billion! This is a clunker. Either they die from the costs of the phase 3 trials, and only the phase 3 trials count, or they are swallowed up. By the way: With CapriSegna, Novo already has the answer to small players like Viking Therapeutics up its sleeve. Amgen brings MariTide, and Amgen usually buys troublesome competitors out of its protocash, see Horizon Therapeutics.
